Microsize is the largest independent pharmaceutical micronization business in North America, and a pioneer in enhancing the dissolution and bioavailability of Active Pharmaceutical Ingredients (APIs). The company has the experience and capabilities to rapidly develop, scale-up, and process APIs and excipients ranging from grams to multi-metric tons, including highly potent compounds. We are THE partner of choice from small biotechs to big pharma, recognized for our speed, responsiveness, and high customer-touch business model. When it comes to your toughest dissolution and bioavailability challenges, Think BIG…….Think Microsize.
Operating from over 100,000sqft, our FDA-inspected GMP facilities comprise an R&D center, analytical development and QC laboratories, multiple manufacturing suites, and large GMP warehousing. Capabilities include handling highly potent compounds (“HPAPI’s”) in both hard wall, and flexible, single-use disposable containment systems. Microsize world-class facilities have seen significant recent investments in containment technologies, Quality Management Systems, and analytical capabilities.
At Microsize, we bring the best of both worlds: providing the high customer-touch, flexibility, and nimbleness of a smaller organization, COMBINED WITH the world-class facilities, quality systems, and capabilities you’d come to expect from a larger global CDMO.
Operating from over 100,000sqft, our FDA-inspected GMP facilities comprise an R&D center, analytical development and QC laboratories, multiple manufacturing suites, and large GMP warehousing. Capabilities include handling highly potent compounds (“HPAPI’s”) in both hard wall, and flexible, single-use disposable containment systems. Microsize world-class facilities have seen significant recent investments in containment technologies, Quality Management Systems, and analytical capabilities.
At Microsize, we bring the best of both worlds: providing the high customer-touch, flexibility, and nimbleness of a smaller organization, COMBINED WITH the world-class facilities, quality systems, and capabilities you’d come to expect from a larger global CDMO.
Employees: 11-50
Founded date: 1994
Investors 1
| Date | Name | Website |
| - | BroadOak C... | broadoak.c... |
Mentions in press and media 3
| Date | Title | Description |
| 12.07.2023 | Daily AI Roundup: Biggest Machine Learning, Robotic And Automation Updates 12th July 2023 | This is our AI Daily Roundup . We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI), Machine Learning, Robotic Process Automation, Fintech, and human-s... |
| 11.07.2023 | Microsize Announces a Strategic Investment into The Solubility Company to Accelerate the US Expansion of a Novel | Microsize announced the strategic investment and partnership with Helsinki-based The Solubility Company. Microsize’s investment accelerates plans for The Solubility Company to open a US-based solubility lab which will be located in Microsiz... |
| 10.07.2023 | The Solubility Company Secures Seed Funding for US Expansion Via Investors Led by Microsize LLC | Solubility logo HELSINKI, FINLAND, July 10, 2023/EINPresswire.com/ -- The Solubility Company Oy proudly announces a strategic investment from a US-based pharma investment group composed of preeminent pharmaceutical CRO/CDMO leaders led by M... |